What is the translation of " SUPSTRATA P-GP-A " in English?

• p-gp substrate

Examples of using Supstrata p-gp-a in Croatian and their translations into English

Kada se primjenjuje istodobno s Lojuxtom valja razmotriti smanjenje doze supstrata P-gp-a.
Dose reduction of the P gp substrate should be considered when used concomitantly with Lojuxta.

Istovremena primjena ulipristalacetata i supstrata P-gp-a nije istražena, pa se interakcija ne može isključiti.
Simultaneous administration of ulipristal acetate and a P-gp substrate has not been studied and an interaction cannot be excluded.

P-gp supstrati: Lomitapid inhibira P-gp in vitro i može povećati apsorpciju supstrata P-gp-a.
P-gp substrates: Lomitapide inhibits P-gp in vitro, and may increase the absorption of P-gp substrates.

Istodobna primjena digoksina, supstrata P-gp-a, s empagliflozinom rezultirala je 6%-tnim povećanjem vrijednosti AUC i 14%-tnim povećanjem vrijednosti Cmax za digoksin.
Co-administration of digoxin, a P-gp substrate, with empagliflozin resulted in a 6% increase in AUC and 14% increase in Cmax of digoxin.

Prema tome, moguće je da kabozantinib može povećati koncentracije u plazmi supstrata P-gp-a koji se primjenjuje istodobno s njim.
Therefore, cabozantinib may have the potential to increase plasma concentrations of co-administered substrates of P-gp.

Ispitanike se mora upozoriti na primjenu supstrata P-gp-a(npr. feksofenadin, aliskiren, ambrisentan, dabigatran eteksilat, digoksin, kolhicin, maravirok, posakonazol, ranolazin, saksagliptin, sitagliptin, talinolol, tolvaptan) za vrijeme primjene kabozantiniba.
Subjects should be cautioned regarding taking a P-gp substrate(e.g., fexofenadine, aliskiren, ambrisentan, dabigatran etexilate, digoxin, colchicine, maraviroc, posaconazole, ranolazine, saxagliptin, sitagliptin, talinolol, tolvaptan) while receiving cabozantinib.

Istodobna primjena apiksabana(20 mg jedanput na dan) i digoksina(0, 25 mg jedanput na dan), supstrata P-gp-a, nije utjecala na AUC ni Cmax digoksina.
Coadministration of apixaban(20 mg once a day) and digoxin(0.25 mg once a day), a P-gp substrate, did not affect digoxin AUC or Cmax.

Ispitanike je potrebno upozoriti u vezi uzimanja supstrata P-gp-a(npr. feksofenadina, aliskirena, ambrisentana, dabigatraneteksilata, digoksina, kolhicina, maraviroka, posakonazola, ranolazina, saksagliptina, sitagliptina, talinolola, tolvaptana) za vrijeme primjene kabozantiniba vvidjeti dio 4.5.
Subjects should be cautioned regarding taking a P-gp substrate(e.g., fexofenadine, aliskiren, ambrisentan, dabigatran etexilate, digoxin, colchicine, maraviroc, posaconazole, ranolazine, saxagliptin, sitagliptin, talinolol, tolvaptan) while receiving cabozantinib see section 4.5.

Elbasvir uzrokuje minimalnu inhibiciju P-gp-a u crijevima ljudi i ne uzrokuje klinički značajno povišenje koncentracije digoksina(supstrata P-gp-a), ali povećava AUC u plazmi za 11.
Elbasvir has minimal intestinal P-gp inhibition in humans, and does not result in clinically relevant increases in concentrations of digoxin(a P-gp substrate), with an 11% increase in plasma AUC.

Stoga se preporučuje odvojiti uzimanje ulipristalacetata i supstrata P-gp-a(npr. dabigatran-etaksilat, dikosin, feksofenadin) za barem 1, 5 sat.
It is therefore recommended that co-administration of ulipristal acetate and P-gp substrates(e.g. dabigatran etexilate, digoxin, fexofenadine) should be separated in time by at least 1.5 hours.

Dapagliflozin: U ispitivanjima interakcija provedenima sa zdravim ispitanicima, uglavnom uz primjenu jedne doze, dapagliflozin nije izmijenio farmakokinetiku metformina, pioglitazona[ supstrata CYP2C8( značajan) i CYP3A4( sporedan)], sitagliptina, glimepirida( supstrata CYP2C9), hidroklorotiazida, bumetanida, valsartana, digoksina( supstrata P-gp-a) ni varfarina( S-varfarina, supstrata CYP2C9) kao ni antikoagulantni učinak varfarina mjeren INR-om.
Dapagliflozin: In interaction studies conducted in healthy subjects, using mainly a single-dose design, dapagliflozin did not alter the pharmacokinetics of metformin, pioglitazone[a CYP2C8(major) and CYP3A4(minor) substrate], sitagliptin, glimepiride(a CYP2C9 substrate), hydrochlorothiazide, bumetanide, valsartan, digoxin(a P-gp substrate) or warfarin(S-warfarin, a CYP2C9 substrate), or the anticoagulatory effects of warfarin as measured by INR.

Podaci iz in vivo istraživanja pokazuju kako uzimanje ulipristalacetata(u jednoj tableti od 10 mg) 1, 5 sat prije uzimanja supstrata P-gp-a feksofenadina(60 mg) nema klinički relevantnih učinaka na farmakokinetičko djelovanje feksofenadina.
In vivo results show that ulipristal acetate(administered as a single 10 mg tablet) 1.5 hour before administration of the P-gP substrate fexofenadine(60 mg) has no clinically relevant effects on the pharmacokinetic of fexofenadine.

Istodobna primjena ponovljenih doza jakog inhibitora P-gp-a kinidina(600 mg, dvaput dnevno) ili umjerenog inhibitora/supstrata P-gp-a temsirolimusa(25 mg) nema klinički značajan učinak na farmakokinetiku lenalidomida 25 mg.
Co-administration of multiple doses of the strong P-gp inhibitor quinidine(600 mg, twice daily) or the moderate P-gp inhibitor/substrate temsirolimus(25 mg) has no clinically relevant effect on the pharmacokinetics of lenalidomide 25 mg.

Nintedanib je supstrat P-gp-a vidjeti dio 5.2.
Nintedanib is a substrate of P-gp see section 5.2.

In vitro ispitivanja su pokazala da je afatinib supstrat P-gp-a i BCRP-a.
In vitro studies have demonstrated that afatinib is a substrate of P-gp and BCRP.

In vitro ispitivanja pokazuju da je lenvatinib supstrat P-gp-a i BCRP-a.
In vitro studies indicate that lenvatinib is a substrate for P-gp and BCRP.

Prema ispitivanju provedenom u zdravih dobrovoljaca, netupitant ne utječe na izloženost digoksinu, supstratu P-gp-a, ali povećava njegov Cmax za 1, 09 puta 90% CI 0, 9-1, 31.
In a study performed in healthy volunteers, netupitant does not affect the exposure of digoxin, a P-gp substrate, whereas it increases its Cmax by fold 90%CI 0.9-1.31.

Kod zdravih ispitanika, AUC(0-t) i Cmax digoksina(supstrat P-gp-a) su bili povišeni za 23% odnosno 29% kada je bio primijenjen istodobno, zbog inhibicije P-gp-a vandetanibom.
In healthy subjects, the AUC(0-t) and Cmax for digoxin(P-gp substrate) were increased by 23% and 29% respectively, when given together due to P-gp inhibition by vandetanib.

Stoga istodobna primjena lumakaftora/ivakaftora sa supstratima P-gp-a(npr. digoksin) može promijeniti izloženost ovim supstratima..
Therefore, concomitant use of lumacaftor/ivacaftor with P-gp substrates(e.g., digoxin) may alter the exposure of these substrates..

Stoga se preporučuje oprez kada se netupitant kombinira s digoksinom ili s drugim supstratima P-gp-a kao što su dabigatran ili kolhicin.
Therefore, caution is recommended when netupitant is combined with digoxin or with other P-gp substrates such as dabigatran, or colchicine.

Rezultati in vitro pokazali su skromnu mogućnost da avanafil djeluje kao supstrat P-gp i inhibitor P-gp s digoksinom kao supstratom pri koncentracijama nižim od izračunate intestinalne koncentracije.
In vitro results showed for avanafil a modest potential for acting as P-gp substrate and P-gp inhibitor with digoxin as a substrate at concentrations lower than the calculated intestinal concentration.

Inhibicijski potencijal mirabegrona na P-gp treba uzeti u obzir kada se Betmiga kombinira s osjetljivim supstratima P-gp, npr. dabigatranom.
The potential for inhibition of P-gp by mirabegron should be considered when Betmiga is combined with sensitive P-gp substrates e.g. dabigatran.

Na temelju in vitro podatka, sonidegib nije supstrat P-gp-a, BCRP-a ili proteina višestruke rezistencije na lijekove 2 MRP2.
Based on in vitro data, sonidegib is not a substrate of P-gp, BCRP or multi-resistance protein 2 MRP2.

In vitro ispitivanja su pokazala da ibrutinib nije supstrat P-gp-a, niti drugih glavnih prijenosnika, osim OCT2.
In vitro studies indicated that ibrutinib is not a substrate of P-gp, nor other major transporters, except OCT2.

Vidjeti tablicu 3 za primjere interakcija s osjetljivim supstratima P-gp-a(digoksin), BCRP-a(rosuvastatin) i OATP-a pravastatin.
See Table 3 for examples of interactions with sensitive substrates of P-gp(digoxin), BCRP(rosuvastatin), and OATP pravastatin.

In vitro eksperimenti s humanim Caco-2 stanicama ukazuju na to da je simeprevir supstrat P-gp-a.
In vitro experiments with human Caco-2 cells indicated that simeprevir is a substrate of P-gp.

Tikagrelor je također supstrat glikoproteina(P-gp) i slabi inhibitor P-gp-a, te može povećati izloženost supstratima P-gp-a.
Ticagrelor is also a P-glycoprotein(P-gp) substrate and a weak P-gp inhibitor and may increase the exposure of P-gp substrates.

Potreban je oprez kad se vemurafenib primjenjuje istodobno sa supstratima P-gp-a(npr. aliskirenom, ambrisentanom, kolhicinom, dabigatraneteksilatom, digoksinom, everolimusom, feksofenadinom, lapatinibom, maravirokom, nilotinibom, posakonazolom, ranolazinom, sirolimusom, sitagliptinom, talinololom, topotekanom) te se može razmotriti smanjenje doze istodobno primijenjenog lijeka, ako je to klinički indicirano.
Caution should be exercised when dosing vemurafenib concurrently with P-gp substrates(e.g. aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, sirolimus, sitagliptin, talinolol, topotecan) and dose reduction of the concomitant medicinal product may be considered, if clinically indicated.

Stoga ponatinib može smanjiti plazmatske koncentracije istovremeno primijenjenih supstrata P-gp(poput digoksina, dabigatrana, kolhicina, pravastatina) ili BCRP(poput metotreksata, rosuvastatina, sulfasalazina) i može povećati njihov terapijski učinak i nuspojave.
Therefore, ponatinib may have the potential to increase plasma concentrations of co-administered substrates of P-gp(e.g., digoxin, dabigatran, colchicine, pravastatin) or BCRP(e.g., methotrexate, rosuvastatin, sulfasalazine) and may increase their therapeutic effect and adverse reactions.

Eliglustat je in vitro inhibitor P-gp i CYP2D6; istovremena primjena eliglustata i tvari supstrata P-gp ili CYP2D6 može povećati koncentracije tih tvari u plazmi.
Eliglustat is an inhibitor of P-gp and CYP2D6 in vitro; concomitant administration of eliglustat with P-gp or CYP2D6 substrate substances may increase the plasma concentration of those substances.